Publications by authors named "Miltiadis Markatos"
Remission of asthma can occur as part of the natural history of the disease; however, the use of biologics can result in disease remission in some patients. In this post hoc analysis of the RELIght study, we aimed to evaluate clinical remission in real life among patients treated with mepolizumab, to detect possible differences between "remitters" and "nonremitters," and to evaluate possible predictors of remission. Clinical remission was defined as the absence of asthma exacerbations, discontinuation of oral corticosteroids (OCS), achievement of asthma control (Asthma Control Test [ACT] ≥ 20), and stable or improved lung function.
View Article and Find Full Text PDFSARS-Cov-2 Infection in Severe Asthma Patients Treated With Biologics.
J Allergy Clin Immunol Pract
October 2022
Article Synopsis
- The study aimed to observe the risks of COVID-19 in patients with severe asthma who are treated with biologics during the pandemic.
- Data was collected from 591 severe asthmatics across Greece, revealing that only 4.4% tested positive for SARS-CoV-2, with a small number requiring hospitalization.
- Findings suggest that severe asthma patients on biologics do not have a higher risk of COVID-19 infection or adverse outcomes compared to the general population.
Novel coronavirus disease 2019 (COVID-19) is an infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a worldwide pandemic and affected more than 227 countries or territories, resulting in more than 179 million cases with over 3.890.00 deaths, as of June 25, 2021.
View Article and Find Full Text PDFThe efficacy and safety of omalizumab in patients with severe allergic asthma have been established in both randomized controlled trials and real-life studies. To evaluate the sustained effectiveness and safety of long-term treatment with omalizumab in a real-world setting. In this retrospective study, we included patients treated with omalizumab for at least 8 years in four asthma clinics in Greece.
View Article and Find Full Text PDFIntroduction: Mepolizumab is a monoclonal antibody against IL-5 for the treatment of severe eosinophilic asthma. The aim of the current study was to present a predesigned interim analysis of the data of patients who have completed 1 year of therapy with mepolizumab.
Methods: This study is a prospective multicenter, noninterventional 2-year observational study and aims to describe the clinical benefit and safety profile of mepolizumab in patients with severe eosinophilic asthma.
Background: Omalizumab is a recombinant humanized anti-IgE monoclonal antibody indicated as an add-on treatment for severe allergic asthma, inadequately controlled despite high dose of inhaled corticosteroids (ICS) and long-acting b2-agonists.
Objectives: Medical registries were used to evaluate the 4 months, 1 and 4 years effectiveness of omalizumab treatment, in a non-interventional, observational "real-life" study.
Methods: Sixty patients with severe persistent allergic asthma from 5 South-Eastern Mediterranean centres from Crete and Cyprus were evaluated.